Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21750001 | 0.89 | ALDH1A1 (0.46) | MAOAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL21750054 | 0.89 | MAOA (0.44) | MAOAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL29860615 | 0.89 | ALDH1A1 (0.46) | MAOAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL303302 | 0.83 | MAOA (0.61) | MAOAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL29860722 | 0.83 | MAOA (0.61) | MAOAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL15580925 | 0.83 | MAOA (0.61) | MAOAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL21749994 | 0.79 | MAOA (0.42) | MAOAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL6370986 | 0.76 | MAOA (0.77) | MAOAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL3822356 | 0.76 | CA12 (0.42) | GAARXFP1POLBNPC1RAB9A | |
| SCHEMBL11412153 | 0.75 | ALDH1A1 (0.47) | MAOAALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120202243-A | Thermosetting resin composition, cured film, substrate, and electronic component | 捷恩智株式会社 | 2025-06-24 | — | — | CN | disclosed |
| EP-1423115-B9 | ANTIANGIOGENIC ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | CHILDRENS MEDICAL CENTER (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-1423115-B1 | ANTIANGIOGENIC ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | CHILDRENS MEDICAL CENTER (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070105903-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | CELGENE CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-7153867-B2 | Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator | CELGENE CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1423115-A4 | SYNTHESIS AND ANTI-TUMOR ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | CHILDRENS MEDICAL CENTER (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1423115-A2 | SYNTHESIS AND ANTI-TUMOR ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | The Children's Medical Center Corporation (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20030139451-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | CHILDREN'S MEDICAL CENTER CORPORATION, THE | 2003-07-24 | — | — | US | disclosed |
| WO-2003014315-A2 | SYNTHESIS AND ANTI-TUMOR ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139451-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | VEGFA, FLT4, FLT1 | MAOA 2907/4885ALDH1A1 2713/4885KDM4E 1098/4885 |
| US-20070105903-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | VEGFA, FLT4, FLT1 | MAOA 2907/4885ALDH1A1 2713/4885KDM4E 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.